Status In progress
Process STA pre-2018
ID number 885

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen


Companies sponsors Shire
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Patients On Intravenous & Nasogastric Nutrition Therapy
  Short Bowel Survivors & Friends
Professional groups Lennard Jones Intestinal Failure Unit, St Marks Hospital
  Royal College of Physicians


Comparator companies Accord Healthcare (cimetidine, omeprazole, ranitidine) (not participating)
  Allergan (lansoprazole, omeprazole) (not participating)
  Alliance pharmaceuticals (ranitidine) (not participating)
  AstraZeneca (omeprazole) (not participating)
  Aurobindo Pharma (ranitidine) (not participating)
  Bristol Laboratories (ranitidine) (not participating)
  Chugai Pharma (sucralfate) (not participating)
  Concordia International (ranitidine) (not participating)
  Dexcel Pharma (omeprazole) (not participating)
  Dr Reddy’s Laboratories (omeprazole) (not participating)
  GlaxoSmithKline (ranitidine) (not participating)
  Janssen-Cilag (loperamide) (not participating)
  Lupin (lansoprazole) (not participating)
  McNeil Products (loperamide) (not participating)
  Omega Pharma (ranitidine) (not participating)
  Pfizer (lansoprazole) (not participating)
  Ranbaxy (lansoprazole) (not participating)
  Reckitt Benckiser Healthcare (loperamide, ranitidine) (not participating)
  Rosemont (cimetidine, ranitidine) (not participating)
  Sandoz (omeprazole) (not participating)
  SSL International (loperamide) (not participating)
  The Boots Company (loperamide, omeprazole, ranitidine) (not participating)
  Wockhardt UK (loperamide) (not participating)
  Zentiva (lansoprazole, loperamide, omeprazole) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
15 March 2021 The company has informed NICE that they wish to withdraw their current evidence submission and resubmit to NICE to begin this topic again. In the meantime, NICE will publish terminated guidance for this appraisal and schedule the new submission into the work programme later in 2021.
09 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
06 August 2019 The manufacturer of teduglutide has asked NICE to pause this appraisal further to them entering into discussions with NHS England about their value proposition. We have agreed to this. Therefore no appeal or publication will take place at this time.
12 July 2019 - 26 July 2019 Final appraisal document
30 May 2019 Committee meeting: 4
03 October 2018 Committee meeting: 3
31 July 2018 NICE has asked the Decision Support Unit (DSU) to prepare a report. We will consult on this report with registered consultees and commentators. The Committee will then consider this appraisal at their 3 October meeting.
31 January 2018 Following the second Appraisal Committee on 4 January this appraisal has been suspended because the company has provided more information that needs to be considered by NICE, and because some technical issues need to be explored in more detail. We will update you on the revised timelines as soon as possible.
04 January 2018 Committee meeting: 2
13 November 2017 - 04 December 2017 Appraisal consultation
18 October 2017 Committee meeting: 1
26 May 2017 Invitation to participate
01 April 2016 Draft scope documents
15 March 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance